Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2011

View Archived Issues

Promising data described from several trials of natalizumab in RRMS

Incyte and Pfizer disclose favorable preclinical data on chemokine CCR2 receptor antagonist

Phase III results show immunogenicity of quadrivalent flu vaccine in children

Actilyse approved in 15 European countries to treat acute ischemic stroke

Nitazoxanide evaluated in viral respiratory infections

Researchers at Novartis disclose new kinesin-like protein KIF11 inhibitors

Novel candidate therapeutics prepared for ophthalmic diseases

Sanofi presents novel protease-activated PAR1 receptor antagonists

New MAP kinase p38 inhibitors designed by RespiVert

NanoViricides raises funds to advance new influenza candidate

Synageva BioPharma and Trimeris complete merger

Acadia Pharmaceuticals clear to test AM-831 in clinic

Novel HIV reverse transcriptase inhibitor prodrugs disclosed

Functional Genetics completes first-in-human FGI-101-1A6 trial

FDA recognizes Velcade extends survival of patients with multiple myeloma

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Daiichi Sankyo gains Brazilian rights to drug for overactive bladder

First RENAISSANCE phase III trial does not meet primary endpoint

Pilot study evaluates apremilast in ankylosing spondylitis

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

FDA approves U.S. market return for Octagam

Artisan Pharma becomes wholly owned subsidiary of Asahi Kasei Pharma

Amgen to pay ImmunoGen milestone for use of TAP technology

Recordati's Normosang approved in Russia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...